[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dystonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dystonia":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,39,79,104,135,156,165,185,210,239,269,289,322,343,376,408,431,453,478,504,523,546,573,597,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054277","deep-brain-stimulation-dbs-retrospective-outcomes-study-100054277",false,"NCT03664609","Deep Brain Stimulation (DBS) Retrospective Outcomes Study","Inclusion Criteria:\n\n* Must be previously treated with or eligible for implantation with a deep brain stimulation system\n\nExclusion Criteria:\n\n* No Exclusion Criteria","ALL",{"count":18,"type":19},5000,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.",[23,24,25],"Parkinson Disease","Essential Tremor","Dystonia","RECRUITING","2026-07-10",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2019-03-12",{"date":34,"type":19},"2028-12",{"name":36,"class":37},"Boston Scientific Corporation","INDUSTRY",19,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":63,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681","NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","5 Years","17 Years",{"count":50,"type":19},40,"INTERVENTIONAL",[53],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[56,57,58,25,59,60,61,62],"Pediatric Disorder","Genetic Predisposition","Dystonia, Secondary","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[64,65,25,66,67],"Pediatric","Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","2026-06-19",{"date":70,"type":30},"2026-06-24",{"date":72,"type":30},"2024-10-15",{"date":74,"type":19},"2029-12-31",{"name":76,"class":77},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":51,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":78},"100617942","quantifying-motor-network-dynamics-to-predict-and-enhance-outcomes-in-pediatric-dystonia-100617942","NCT07325175","Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia","Inclusion Criteria:\n\n* For dystonia subjects:\n* Dx of dystonia (with and without DBS)\n* willingness and ability to complete study protocols.\n* For Typically Developing Controls:\n* normal developmental milestones\n* absence of any neuropsychiatric disorder\n* no significant medical condition.\n\nExclusion Criteria:\n\n* history of epilepsy\n* presence of implanted medical devices (except DBS in dystonia subjects)\n* lack of cognitive or physical ability to complete study protocol.",true,"6 Years","21 Years",{"count":89,"type":19},75,[91],"NA","The goal of this study is to understand the development and progression of childhood dystonia, a movement disorder, in children. The main questions it aims to answer are:\n\nHow does the activity of the neural network evolve in children with dystonia in the context of motor development? What are the effects of chronic and active stimulation on cortical and subcortical motor network function in children with deep brain stimulation (DBS)?\n\nParticipants will:\n\n* Undergo noninvasive electrophysiological measurements (EEG, EMG) to quantify neural network activity. They will be tested at rest and during a simple motor reaction task.\n* Children with DBS will be assessed in the on and off DBS state to assess effects of chronic and active changes in motor network function.",[25,64,94,95],"Deep Brain Stimulation","Motor Development","2026-06-15",{"date":98,"type":30},"2026-06-16",{"date":100,"type":30},"2024-01-01",{"date":74,"type":19},{"name":103,"class":77},"Children's Hospital Medical Center, Cincinnati",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":51,"phases":115,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100616321","phase-2-a-study-to-evaluate-the-efficacy-safety-and-tolerability-of-vim0423-in-individuals-with-isolated-dystonia-100616321","NCT07304089","A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)","Inclusion Criteria:\n\n* Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).\n* The participant has a clinical diagnosis of isolated dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.\n* The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.\n* The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.","18 Years","65 Years",{"count":114,"type":19},100,[116],"PHASE2","Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.\n\nThe main objectives of this clinical trial are to determine the following:\n\n* Does VIM0423 therapy improve dystonia symptoms compared to placebo?\n* Is VIM0423 well tolerated in individuals with isolated dystonia? and\n* Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?",[25],[25,120,121,122,123,124,125],"Isolated Dystonia","Primary Dystonia","Cervical Dystonia","Segmental Dystonia","Multi-focal Dystonia","Generalized Dystonia","2026-06-11",{"date":96,"type":30},{"date":129,"type":30},"2026-02-05",{"date":131,"type":19},"2027-05",{"name":133,"class":37},"Vima Therapeutics",37,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":20,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100558630","radiofrequency-rf-ablation-prospective-outcomes-study-for-central-nervous-system---rapid-for-cns-100558630","NCT06553625","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)\n* Signed a valid, IRB\u002FEC\u002FREB-approved informed consent form\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Directions for Use (DFU)\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":143,"type":19},200,"24 Months","The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.",[23,25,24,147],"Movement Disorders","2026-06-10",{"date":126,"type":30},{"date":151,"type":30},"2024-01-29",{"date":153,"type":19},"2035-12",{"name":36,"class":37},4,{"id":157,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":159,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":164,"locationsCount":38},"100336760",{"count":18,"type":19},[23,24,25],{"date":161,"type":30},"2026-06-12",{"date":32,"type":30},{"date":34,"type":19},{"name":36,"class":37},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":16,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":175,"studyType":20,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100261711","vercise-dbs-dystonia-prospective-study-100261711","NCT02686125","Vercise™ DBS Dystonia Prospective Study","Prospective Study of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia","Inclusion Criteria (IC):\n\n* IC1. Meets criteria established in the locally applicable Vercise System Directions for Use (DFU) for dystonia.\n* IC2. At least 7 years old. Parent or guardian consent is required in patients who are younger than 18 years at the time of consent.\n\nExclusion Criteria (EC):\n\n* EC1. Meets any contraindication in the Vercise System locally applicable Directions for Use.","7 Years",{"count":174,"type":19},300,"3 Years","To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.",[25],{"date":126,"type":30},{"date":180,"type":30},"2016-03-07",{"date":182,"type":19},"2030-12",{"name":36,"class":37},36,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":51,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":78},"100177251","deep-brain-stimulation-surgery-for-movement-disorders-100177251","NCT01581580","Deep Brain Stimulation Surgery for Movement Disorders","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must meet all the following criteria:\n\nBe 18 years of age or older.\n\nAble to provide informed consent.\n\nHave a clinical diagnosis of one of the following as confirmed by the NIH movement disorders clinic team and the multi-disciplinary DBS surgical conference, and deemed as appropriate for the use of Deep Brain Stimulation therapy:\n\n* idiopathic PD not adequately controlled with medication or\n* primary dystonia that is medically refractory, or\n* ET that is not adequately controlled by medications or constitutes a significant functional disability.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\nAre unable or unwilling to give informed consent to the research procedures.","99 Years",{"count":143,"type":19},[91],"Background:\n\n\\- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest. It is used to stimulate the areas of the brain that affect movement. Stimulating these areas helps to block the nerve signals that cause abnormal movements. Researchers also want to record the brain function of people with movement disorders during the surgery.\n\nObjectives:\n\n* To study how DBS surgery affects Parkinson s disease, dystonia, and tremor.\n* To obtain information on brain and nerve cell function during DBS surgery.\n\nEligibility:\n\n\\- People at least 18 years of age who have movement disorders, like Parkinson's disease, essential tremor, and dystonia.\n\nDesign:\n\n* Researchers will screen patients with physical and neurological exams to decide whether they can have the surgery. Patients will also have a medical history, blood tests, imaging studies, and other tests. Before the surgery, participants will practice movement and memory tests.\n* During surgery, the stimulator will be placed to provide the right amount of stimulation for the brain. Patients will perform the movement and memory tests that they practiced earlier.\n* After surgery, participants will recover in the hospital. They will have a followup visit within 4 weeks to turn on and adjust the stimulator. The stimulator has to be programmed and adjusted over weeks to months to find the best settings.\n* Participants will return for followup visits at 1, 2, and 3 months after surgery. Researchers will test their movement, memory, and general quality of life. Each visit will last about 2 hours.",[196,24,25],"Parkinson's Disease",[196,94,198,199,25,23,24],"Neurophysiology","Movement Disorder","2026-06-04",{"date":202,"type":30},"2026-06-05",{"date":204,"type":30},"2011-08-17",{"date":206,"type":19},"2029-12-01",{"name":208,"class":209},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":51,"phases":220,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":155},"100592873","long-read-genome-sequencing-for-the-molecular-diagnosis-of-dystonia-100592873","NCT06999096","Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia","Evaluation of the Value of Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia: a Prospective Multicenter Study","GenoDYT","Inclusion criteria - Index case:\n\n* Index case affected by familial dystonia (≥1 first-degree relative affected) and\u002For sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program.\n* Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis.\n* Ability to understand and sign informed consent by the index case and\u002For their parents or legal guardians for patients under 18 years of age.\n* Availability of a blood sample from the index case and at least two relatives, either affected or unaffected.\n\nInclusion criteria - Relatives:\n\n* Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis.\n* Ability to understand and sign informed consent.\n\nExclusion criteria:\n\n* Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme.\n* Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study.\n* Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).",{"count":219,"type":19},150,[91],"Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS).\n\nMolecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-in some cases-targeted therapies. For instance, GNAO1-related dystonia may respond to deep brain stimulation, while dopa-responsive dystonia benefits from levodopa.\n\nDespite advances, srWGS has key limitations, especially for detecting repeat expansions, SVs, and phasing alleles. This likely explains the low diagnostic yield in dystonia compared to other neurological disorders, with over 70% of cases remaining unsolved.\n\nLong-read sequencing (lrWGS), such as Oxford Nanopore technology, overcomes many of these challenges by reading native DNA fragments thousands of bases long. It enables comprehensive detection of SNVs, indels, SVs, CNVs, methylation changes, and repeat expansions-including known and newly discovered pathogenic expansions (e.g., in NOTCH2NLC). It also allows phasing without parental samples, which is crucial in recessive cases.\n\nThe investigators propose that lrWGS could significantly increase the diagnostic yield in dystonia, improving patient care, enabling appropriate genetic counseling, and paving the way for personalized treatment strategies.",[25,147,223,224],"Combined Dystonia","Complex Dystonia",[25,226,227,228,229],"Genome Sequencing","Long-read Sequencing","Molecular diagnosis","Neurogenetics","2026-05-19",{"date":232,"type":30},"2026-05-20",{"date":234,"type":19},"2026-04-22",{"date":236,"type":19},"2030-08",{"name":238,"class":77},"University Hospital, Strasbourg, France",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":16,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":78},"100571187","multimodal-investigation-of-cortico-basal-ganglia-thalamo-cortical-network-dynamics-in-dystonic-patients-with-deep-brain-stimulation-100571187","NCT06716983","Multimodal Investigation of Cortico-Basal Ganglia-Thalamo-Cortical Network Dynamics in Dystonic Patients With Deep Brain Stimulation","Multimodal Investigation of Cortico-Basal Ganglia-Thalamo-Cortical (CBGTC) Network Dynamics in Dystonic Patients With Deep Brain Stimulation (DBS)","DYScover","Inclusion Criteria:\n\n* Patients diagnosed with idiopathic or genetic dystonia who have already undergone DBS surgery of the globus pallidus internus\n* Patient implanted with a neurostimulator capable of chronically recording LFPs and which is fully compatible with magnetic fields up to 3 Tesla.\n* Age\\>12 years\n\nExclusion Criteria:\n\n* Evidence of CNS pathology or any other acquired conditions (perinatal, infective, toxic, neoplastic, vascular, psychogenic) responsible for the dystonia phenomenology,\n* Focal distribution of dystonia\n* Contraindications to brain MRI or EEG\u002FMEG\n* Adult subjects unable to express consent to inclusion in the study\n* Pregnancy, and breastfeeding.","12 Years",{"count":249,"type":19},15,"The goal of this prospective open label study is to elucidate the pathophysiology of dystonia and to understand how deep brain stimulation (DBS) influences brain networks. The investigators will enroll patients with dystonia implanted with DBS of the Globus Pallidus internus (GPi) with sensing implantable neurostimulators, capable of measuring GPi local field potentials (LFPs).\n\nThe main questions it aims to answer are:\n\n* does DBS influence pallidal LFPs in the long term?\n* how the basal-ganglia-thalamo-cortical circuit is modified after DBS?\n* do LFPs changes correlate with clinical improvement? Participants will undergo to serial clinical evaluations, magnetoencephalography (MEG) and functional Magnetic Resonance Imaging (fMRI) studies. Primarily, the data obtained from our study might help in clarifying basic pathological electrophysiological features of dystonia. These features might be secondarily used in future to provide a framework for an effective application of closed-loop DBS in Dystonia.",[25],[25,253,94,254,255,256,257,258,259],"Movement disorders","DBS","Local Field potentials","biomarker","Magnetoencephalography","MEG","fMRI","2026-03-25",{"date":262,"type":30},"2026-03-30",{"date":264,"type":30},"2023-12-28",{"date":266,"type":19},"2026-06",{"name":268,"class":77},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":51,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":78},"100384485","cortical-basal-ganglia-speech-networks-100384485","NCT04286308","Cortical-Basal Ganglia Speech Networks","Inclusion Criteria:\n\n1. Subjects scheduled for DBS implantation, as determined by the clinical multidisciplinary movement disorders board with definitive diagnosis of Parkinson's disease, essential tremor or dystonia.\n2. Subjects able to provide informed consent and comply with task instructions.\n3. Subjects 18-85 years old\n\nExclusion Criteria:\n\n1. Subjects with reported hearing loss.\n2. Non-English-speaking subjects","85 Years",{"count":277,"type":19},80,[91],"In this research study the researchers want to learn more about brain activity related to speech perception and production.",[23,24,25],"2026-03-23",{"date":260,"type":30},{"date":284,"type":30},"2020-10-01",{"date":286,"type":19},"2027-02",{"name":288,"class":77},"Massachusetts General Hospital",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":16,"minAge":297,"maxAge":111,"enrollmentInfo":298,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":299,"conditions":300,"keywords":306,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":78},"100561089","a-multicenter-pediatric-deep-brain-stimulation-registry-100561089","NCT06585618","A Multicenter Pediatric Deep Brain Stimulation Registry","Multicenter Pediatric Deep Brain Stimulation Registry","DBS-R","Inclusion Criteria:\n\n* Female or male patients between ages of 0-18 years.\n* Having received or scheduled to receive DBS for any neurological movement disorder.\n* Parents or legal guardians are able to provide written consent for prospective enrollment.","0 Years",{"count":114,"type":19},"There is limited data on outcomes for children who have undergone deep brain stimulation (DBS) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. This study aims to develop a multicenter pediatric DBS registry that allows multiple sites to share clinical pediatric DBS data. The primary goals are to enable large-scale, well-powered analyses of the safety and efficacy of DBS in the pediatric population and to further explore and refine DBS as a therapeutic option for children with dystonia and other hyperkinetic movement disorders. Given the current scarcity of evidence available to clinicians, this centralized multicenter repository of clinical data is critical for addressing key research questions and improving clinical practice for pediatric DBS.",[25,301,65,302,303,304,305,147,94],"Epilepsy in Children","Tourette Syndrome","Obsessive-Compulsive Disorder","Neurologic Disorder","Movement Disorders in Children",[94,254,307,308,309,310,311,312],"movement disorder","movement disorders in children","dystonia","chorea","dyskinesia","epilepsy","2026-03-16",{"date":315,"type":30},"2026-03-18",{"date":317,"type":30},"2024-07-30",{"date":319,"type":19},"2029-07-30",{"name":321,"class":77},"Boston Children's Hospital",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":51,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":78},"100513209","sleep-specific-dbs-therapy-in-parkinsons-disease-100513209","NCT05962489","Sleep-specific DBS Therapy in Parkinson's Disease","Inclusion criteria:\n\n* Diagnosis of idiopathic PD\n* At least 21 years old\n* Existing or planned 7T brain imaging\n* Surgery at UMN to implant DBS system in GPi or STN with directional lead(s) is planned as part of routine clinical care\n* Surgery at UMN to implant bilateral DBS system in GPi or STN with directional lead(s) is planned as part of routine clinical care (or has already occurred, as long as the initial programming session is at least 2 weeks away)\n\nExclusion criteria:\n\n* Other significant neurological disorder\n* History of dementia\n* Patients with post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment will be excluded from further study\n* Pregnant women\n* Known radiation exposure within the last year that is determined to be unsafe when compounded with the expected radiation dose from intraoperative fluoroscopy to place ECoG strip",{"count":329,"type":19},64,[91],"Sleep-wake disturbances are a major factor associated with reduced quality of life of individuals with Parkinson's disease (PD), a progressive neurological disorder affecting millions of people in the U.S and worldwide. The brain mechanisms underlying these sleep disorders, and the effects of therapeutic interventions such as deep brain stimulation on sleep-related neuronal activity and sleep behavior, are not well understood. Results from this study will provide a better understanding of the brain circuitry involved in disordered sleep in PD and inform the development of targeted therapeutic interventions to treat sleep disorders in people with neurodegenerative disease.",[94,333,25],"Parkinson's Disease and Parkinsonism","2026-03-02",{"date":336,"type":30},"2026-03-03",{"date":338,"type":30},"2023-06-22",{"date":340,"type":19},"2027-08-01",{"name":342,"class":77},"University of Minnesota",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":366,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":78},"100625957","validity-and-reliability-of-the-hypertonia-assessment-tool-hat-in-stroke-patients-100625957","NCT07429383","Validity and Reliability of the Hypertonia Assessment Tool (HAT) in Stroke Patients","Inclusion Criteria:\n\n* Age 18 years and older\n* Clinically and radiologically confirmed diagnosis of stroke (ischemic or -hemorrhagic)\n* Brunnstrom stage between 2 and 6\n* Presence of post-stroke hypertonia (spasticity, dystonia, or rigidity)\n* Cognitive level sufficient to cooperate with assessments (Mini-Mental State Examination (MMSE) score \\>23 or equivalent clinical evaluation)\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age under 18 years\n* Presence of severe accompanying neurodegenerative diseases (e.g., Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis)\n* Presence of primary musculoskeletal disorders affecting motor performance (e.g., rheumatologic diseases, fractures)\n* Brunnstrom stage of 1\n* Severe aphasia, impaired consciousness, or cognitive deficits preventing effective communication and cooperation\n* Any psychiatric disorder that may interfere with study participation","80 Years",{"count":351,"type":19},60,"In this study, the validity and reliability of the Hypertonia Assessment Tool (HAT), which has previously been validated in the pediatric cerebral palsy (CP) population, will be evaluated in adult individuals who have experienced a stroke. The HAT is a specific clinical instrument designed to differentiate subtypes of hypertonia, including spasticity, dystonia, and rigidity.\n\nAccurate classification of hypertonia subtypes following stroke is crucial for guiding rehabilitation strategies. However, the HAT has not yet been validated in the adult post-stroke population. This study will be conducted at the Physical Medicine and Rehabilitation Clinic of SBU Fatih Sultan Mehmet Training and Research Hospital. The study aims to evaluate the validity and reliability of the HAT for use in adults with stroke.",[354,355,25,356,357],"Stroke","Hypertonia","Rigidity","Hemiplegia",[359,309,360,361,362,363,364,365],"hypertonia","rigidity","reliability","validity","hemiplegia","spasticity","stroke","NOT_YET_RECRUITING","2026-02-20",{"date":369,"type":30},"2026-02-24",{"date":371,"type":19},"2026-03-01",{"date":373,"type":19},"2026-10-01",{"name":375,"class":77},"Fatih Sultan Mehmet Training and Research Hospital",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":85,"sex":16,"minAge":111,"maxAge":275,"enrollmentInfo":383,"targetDuration":4,"studyType":51,"phases":385,"briefSummary":386,"conditions":387,"keywords":392,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":78},"100625026","lifus-for-neurological-disorders-100625026","NCT07417280","LIFUS For Neurological Disorders","Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders","Inclusion Criteria:\n\n* 18-85 years of age\n* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)\n* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders\n\nExclusion Criteria:\n\n* History of stroke\n* Comorbid dementia\n* Scored below 22 on the Montreal Cognitive Assessment (MoCA)\n* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)\n* Presence of metal implanted in body that is contraindicated in TMS\u002FMRI\n* Pregnancy\n* Major depression\u002Fpsychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol\n* Major systemic illness or infection",{"count":384,"type":19},50,[91],"Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.",[388,24,389,25,390,391,94],"Parkinson's Disease (PD)","Orthostatic Tremor","Epilepsy","Substance Abuse Disorder",[196,24,389,25,390,391,94,254,393,394,395,396,397,398],"Substance Use Disorder","SUD","PD","LIFUS","Low-Intensity Focused Ultrasound","Neuromodulation","2026-02-10",{"date":401,"type":30},"2026-02-18",{"date":403,"type":30},"2025-12-02",{"date":405,"type":19},"2040-12-31",{"name":407,"class":77},"University Health Network, Toronto",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":430},"100368019","abbott-dbs-post-market-study-of-outcomes-for-indications-over-time-100368019","NCT04071847","Abbott DBS Post-Market Study of Outcomes for Indications Over Time","ADROIT","Inclusion Criteria:\n\n1. Subject is scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 180 days.\n2. Subject, or a legally acceptable representative, must provide written informed consent prior to any study-related procedure.\n\nExclusion Criteria:\n\n1. Subject is currently enrolled or plans to enroll in an investigational study that may confound the results of this study.\n2. Subject has anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results.\n3. Study center is located in the United States, and indication for DBS implant is not Parkinson's disease or disabling tremor.\n4. Study center is located in the United States, and the intended lead implant location is not at, or in close proximity to, the STN, GPi, or VIM thalamus.",{"count":416,"type":19},1000,"The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.",[147,23,24,419,25,121,420],"Tremor","Secondary Dystonia","2026-01-07",{"date":423,"type":30},"2026-01-08",{"date":425,"type":30},"2019-11-26",{"date":427,"type":19},"2030-09",{"name":429,"class":37},"Abbott Medical Devices",48,{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":78},"100617821","predicting-dbs-outcomes-in-dystonia-using-wearable-gait-sensors-100617821","NCT07323602","Predicting DBS Outcomes in Dystonia Using Wearable Gait Sensors","Prediction of Deep Brain Stimulation (DBS) Efficacy in Patients With Dystonia Based on Preoperative Wearable Gait Analysis: A Prospective Observational Study","Inclusion Criteria:\n\n* Clinically diagnosed with primary or isolated dystonia.\n* Scheduled to undergo bilateral Deep Brain Stimulation (DBS) surgery.\n* Able to walk independently or with assistance (sufficient to perform gait analysis).\n* Willing to participate and sign informed consent.\n\nExclusion Criteria:\n\n* History of other neurological disorders affecting gait (e.g., stroke, severe neuropathy).\n* Significant orthopedic issues preventing gait assessment.\n* Cognitive impairment preventing cooperation with study procedures.\n* Previous functional neurosurgery.","70 Years",{"count":384,"type":19},"This study aims to investigate whether preoperative gait characteristics, measured by wearable sensors, can predict the clinical outcomes of Deep Brain Stimulation (DBS) in patients with dystonia. Participants scheduled for DBS surgery will undergo gait analysis using wearable sensors before the procedure. Clinical assessments, including the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) and the SF-36 Health Survey, will be conducted preoperatively and postoperatively to evaluate surgical efficacy and quality of life. The study seeks to identify gait biomarkers that correlate with optimal DBS response.",[25],[309,443,444],"deep brain stimulation","wearable Gait Analysis","2025-12-22",{"date":421,"type":30},{"date":448,"type":30},"2025-08-01",{"date":450,"type":19},"2029-12",{"name":452,"class":77},"Ruijin Hospital",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":462,"conditions":463,"keywords":466,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":476,"locationsCount":78},"100616709","local-field-potentials-in-dystonia-100616709","NCT07309133","Local Field Potentials in Dystonia","Optimising Deep Brain Stimulation for Dystonia Using Local Field Potentials","LFP-DYT","Inclusion Criteria:\n\n* Age 18 years or older at screening.\n* Clear clinical diagnosis of primary dystonia (idiopathic or genetic forms).\n* Candidate for GPi DBS surgery for dystonia treatment.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant neurological or psychiatric disorder (including dementia) that would interfere with outcome evaluation.\n* Participation in a therapeutic research trial within the last year.\n* Diagnosis of functional (psychogenic) dystonia.",{"count":7,"type":19},"The goal of this clinical trial is to learn whether local field potential (LFP) signals recorded from the globus pallidus interna (GPi) using the Medtronic Percept™ deep brain stimulation (DBS) device can help optimize DBS programming for people with dystonia. The study will also explore whether LFP patterns can serve as a biomarker of disease activity and predict treatment response.\n\nThe main questions it aims to answer are:\n\nDo LFP peaks in the alpha-theta range reliably correlate with dystonia severity and clinical characteristics? Can LFP-based programming achieve similar or better clinical outcomes compared to traditional programming methods? How do LFP profiles change with stimulation and other treatments such as botulinum toxin or oral medications?\n\nResearchers will compare two programming approaches:\n\nTraditional programming based on clinical assessment and imaging. LFP-guided programming based on the site and characteristics of LFP peaks\n\nParticipants will:\n\nUndergo DBS surgery for dystonia as part of standard clinical care. Attend regular follow-up visits for DBS programming and outcome assessments. Complete clinical rating scales for dystonia severity, quality of life, cognition, and mood.\n\nTake part in neurophysiological assessments, including surface EMG, EEG, and reaction time tasks.\n\nHave LFP recordings collected using the Medtronic Percept™ device during clinic visits and, where possible, at home using device sensing features.\n\nThis study will help determine whether LFP analysis can shorten the time to optimal DBS settings and improve outcomes for people with dystonia.",[25,464,465],"Dystonia, Focal","Dystonia, Primary",[94,254,467,468,469,198],"Globus Pallidus Interna","Local Field Potentials","Neurostimulation","2025-12-15",{"date":472,"type":30},"2025-12-30",{"date":474,"type":30},"2025-09-04",{"date":34,"type":19},{"name":477,"class":77},"Newcastle-upon-Tyne Hospitals NHS Trust",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":85,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":51,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":78},"100463645","clinical-validation-of-dystonianet-deep-learning-platform-for-diagnosis-of-isolated-dystonia-100463645","NCT05317390","Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds, with age across the lifespan;\n2. Patients will have at least one of the forms of dystonia, including focal dystonia (e.g., laryngeal, cervical, oromandibular, blepharospasm, focal hand, musicians), segmental dystonia, or generalized dystonia;\n3. Patients will have other movement disorders (Parkinson's disease, essential tremor, dyskinesia, myoclonus) and other non-neurological conditions (tic disorders, torticollis, ulnar nerve entrapments, temporomandibular disorders, dysphonia) that mimic dystonic symptoms.\n\nExclusion criteria:\n\n1. Patients who are incapable of giving informed consent;\n2. Patients who are unable to undergo brain MRI due to the presence of certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed or due to pregnancy or breastfeeding at the time of the study.",{"count":416,"type":19},[91],"This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.",[25,488,23,24,489,490,491,492,493,494,495],"Drug Induced Dystonia","Dyskinesias","Myoclonus","Tic Disorders","Torticollis","Ulnar Nerve Entrapment","Temporomandibular Joint Disorders","Dysphonia","2025-11-24",{"date":403,"type":30},{"date":499,"type":30},"2022-06-01",{"date":501,"type":19},"2028-04-30",{"name":503,"class":77},"Massachusetts Eye and Ear Infirmary",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":349,"enrollmentInfo":510,"targetDuration":4,"studyType":51,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":78},"100450791","deep-brain-stimulation-in-laryngeal-dystonia-and-voice-tremor-100450791","NCT05150093","Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor","Inclusion\n\n1. Clinical indications to proceed with DBS implantation, as determined by the clinical multidisciplinary movement disorders board, including: a) definitive diagnosis of essential tremor or dystonia, b) medically refractory disease, c) adequate performance on neuropsychological evaluation as determined by a licensed clinical neuropsychologist.\n2. The ability to comply with test directions, complete pre-operative task training, and provide informed consent.\n3. Age 18-80 years.\n\nExclusion\n\n1\\. Inability to understand or perform the task outlined in the protocol during a pre-surgery training session. 2. Significant hearing loss.\n\n3\\. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as determined by the surgeon, visualized on pre-op MRI or during surgery.",{"count":511,"type":19},120,[91],"The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",[515,516,419,25],"Laryngeal Dystonia","Spasmodic Dysphonia",{"date":403,"type":30},{"date":519,"type":30},"2022-06-21",{"date":521,"type":19},"2027-08-31",{"name":503,"class":77},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":349,"enrollmentInfo":531,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":545},"100611743","chronic-outcome-monitoring-for-dbs-in-dystonia-100611743","NCT07244549","Chronic Outcome Monitoring for DBS in Dystonia","Chronic Neurophyhsiological and Kinematic Biomarker Monitoring in Patients With Dystonia and Pallidal Deep Brain Stimulation","COMMED","Inclusion Criteria:\n\n* Ability to give informed consent for the study, or in pediatric patients, legal guardian or parent willing to give informed consent\n* Diagnosis of dystonia, which may be isolated or generalized\n* Wish to receive surgical intervention with DBS to the internal pallidal globe (GPi)\n* Decision to receive the sensing-enabled neurostimulator (Percept neurostimulator) PC\u002FRC\n* Age 5-80 years\n\nExclusion Criteria:\n\n* Severe psychiatric disorders (BDI\\>20)\n* Other severe medical conditions, that may interfere with the successful paritcipation in the study protocol\n* No consent given",{"count":7,"type":19},"Dystonia is a severe movement disorder involving increased muscular activity and can be very variable. To date, the treatment of dystonia is challenging. One effective therapy is deep brain stimulation (DBS), an invasive therapy, where stimulation electrodes are inserted in deep brain regions and a continuous electrical therapy is delivered via a pacemaker. However, the optimization of the therapy is a long process, up to months and there is no immediate adaptation to different disease states.\n\nThis project aims to improve DBS therapy: The first aim is to learn more about electrical brain activity that could be the feedback signal for individualized therapy. Secondly, the investigators want to gather information about the long-term development of the signal and potential hints for optimal therapy locations that could be acutely used to accelerate therapy optimization. To date, recordings mainly in lab settings, have suggested low-frequency activity as a biomarker for dystonia. Biomarkers are signals that are changed with therapy and that reflect symptom severity. Further understanding of the low-frequency biomarker for dystonia and its applicability in everyday life is one of the objectives in this study. Therefore, using a pacemaker that can also record brain activity, biomarker activity will be recorded for 12 months. At the same time, development of clinical symptoms will be assessed using an application with weekly questionnaires on symptoms and a video diary. At monthly appointments for data saving, resting state as well as motor activity during a finger tapping task will be recorded to also assess the development of side-effects, such as stimulation-induced slowing, and their biomarkers.",[25],[535,536,443,309],"electrophysiology","biomarkers","2025-11-17",{"date":496,"type":30},{"date":540,"type":30},"2024-08-16",{"date":542,"type":19},"2028-03-30",{"name":544,"class":77},"Charite University, Berlin, Germany",3,{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":51,"phases":554,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":78},"100607556","deep-anterior-cerebellar-stimulation-in-treatment-of-poststroke-spasticity-and-motor-function-impairment-100607556","NCT07190092","Deep Anterior Cerebellar Stimulation in Treatment of Poststroke Spasticity and Motor Function Impairment.","Inclusion Criteria:\n\n* One time stroke that occurred 9-36 months ago\n* Ischemic or hemorrhagic stroke\n* Spastic paresis of at least one limb\n* At least 3 months of poststroke rehabilitation in the past\n* No improvement of spasticity\u002Fmotor function for at least 3 months\n\nExclusion Criteria:\n\n* Seizures after the stroke\n* Depression\n* Severe sensory deficits\n* Anosognosia\n* Moderate to severe hemispatial neglect\n* Others contraindications for the DBS procedure, e.g. coagulopathy, decompensated chronic disease, etc.\n* Contraindication for MRI\n* No poststroke rehabilitation",{"count":553,"type":19},12,[91],"The aim of this clinical trial is to determine whether deep brain stimulation (DBS) interventions improve rehabilitation and functional recovery in patients with post-stroke spasticity who meet the other inclusion criteria listed below.\n\nPrimary question(s) to be answered:\n\nIs DBS stimulation effective in treating post-stroke spasticity? What stimulation frequency is most effective in treating post-stroke spasticity?\n\nStudy participants will:\n\n* Undergo surgery to implant a DBS electrode targeting the DRTt (dentate-rubro-thalamic tract ) in close proximity of the dentate nucleus of the cerebellum ipsilateral to the spastic side of the body.\n* Each patient will then receive an initial stimulation frequency of 130 Hz (arm 1) and will be assigned to a 4- to 6-week rehabilitation program. After this period, the participant will return for a follow-up visit for a clinical evaluation.\n* The frequency will then be changed to 70Hz (arm 2). Patients who have undergone this change will also undergo a rehabilitation period of 4 to 6 weeks. After this period, they will return to the Clinic for a follow-up evaluation.\n* The frequency will then be changed to 30Hz (arm 3). Patients who have undergone this change will also undergo a rehabilitation period of 4 to 6 weeks.\n\nResearchers will compare the results obtained from patients in each arm to determine the clinical effects of stimulation and whether they are dependent on the stimulation frequency.",[557,25],"Post Stroke Spasticity",[559,560,561,443,562,563],"dentate nucleus","DRTt","dentate-rubro-thalamic tract","post-stroke spasticity","rehabilitation","2025-09-23",{"date":566,"type":30},"2025-09-24",{"date":568,"type":30},"2024-09-01",{"date":570,"type":19},"2028-12-30",{"name":572,"class":77},"Jan Biziel University Hospital No 2 in Bydgoszcz",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":16,"minAge":111,"maxAge":111,"enrollmentInfo":580,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":78},"100511762","observational-study-on-functional-overlay-in-patients-with-movement-disorders-100511762","NCT05943652","Observational Study on \"Functional Overlay\" in Patients With Movement Disorders","Prevalence and Clinical Presentation of Functional Neurological Disorders in Patients With Movement Disorders - A Cross-sectional Study in the Movement Disorders Clinic of the Department of Neurology, Medical University of Graz","Inclusion Criteria:\n\n* Functional or non-functional movement disorder\n* 18 to 80 years\n\nExclusion Criteria:\n\n* Patient is not able to consent\n* Patient is not able to understand \u002F speak German fluently (questionnaires are available only in German)",{"count":581,"type":19},216,"The goal of this observational study is to learn about functional neurological disorders in patients with common non-functional movement disorders (\"functional overlay\"). The main questions it aims to answer are:\n\n* What is the frequency of functional neurological disorders in patients with non-functional movement disorders (functional overlay)?\n* What are the characteristics of functional neurological disorders in patients with non-functional movement disorders?\n\nParticipants will be examined clinically and electrophysiologically, the examinations consist of:\n\n* a neurological examination\n* neuropsychological testing\n* electrophysiological tremor diagnostic\n* questionnaires about psychological, biological and social risk factors\n\nResearchers will compare patients with functional motor disorders to patients wit non-functional movement disorders to see if they differ from each other regarding the functional symptoms.",[584,23,419,25],"Conversion Disorder",[586,587,588],"Accelerometry","Patient Health Questionnaire","Neuropsychology",{"date":590,"type":30},"2025-09-29",{"date":592,"type":30},"2023-01-01",{"date":594,"type":19},"2026-06-30",{"name":596,"class":77},"Medical University of Graz",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":16,"minAge":86,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":78},"100100843","physiological-brain-atlas-development-100100843","NCT00575081","Physiological Brain Atlas Development","Brain Atlas","Inclusion Criteria:\n\n* All patients who are recommended for Stereotactic Brain procedures\n* Any patient who has agreed to undergo a Stereotactic Brain procedure\n* Patients age under 6 -90 years old\n\nExclusion Criteria:\n\n* Patients who fail recommendation for Stereotactic Brain procedures\n* Patients not consented for Stereotactic Brain procedures\n* Patients outside the age range of 6 -90 years old\n* Patients or legal guardians not able to provide informed consent","90 Years",{"count":18,"type":19},"The NIH grant has funded the development of a physiological brain atlas registry that will allow us to significantly improve the data collectioin and use of physiological data into a normalized brain volume. This initially was used to improve DBS implants for Parkinson's Disease, Dystonia, Essential Tremor, and OCD, but now includes data acquired during all stereotactic brain procedures.",[196,608,25,24,390],"Obsessive Compulsive Disorder",[610],"Physiological Brain Atlas, Brain registry, Brain database","2025-08-09",{"date":613,"type":30},"2025-08-12",{"date":615,"type":4},"2006-08",{"date":617,"type":19},"2026-08",{"name":619,"class":77},"Vanderbilt University Medical Center",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":16,"minAge":627,"maxAge":275,"enrollmentInfo":628,"targetDuration":4,"studyType":51,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":78},"100490262","effects-of-exercise-on-dystonia-pathophysiology-100490262","NCT05663840","Effects of Exercise on Dystonia Pathophysiology","Progressive Resistance Exercise and Dystonia Pathophysiology.","Inclusion Criteria:\n\n* Patients have predominantly focal cervical dystonia and whose diagnosis will be confirmed by a movement disorders specialist following criteria recommended by Movement Disorders Society.\n* Moderate disease severity.\n* Are 30 to 85 years old\n* Are able to tolerate exercise sessions.\n* Reporting suboptimal clinical benefits despite receiving maximally tolerated doses of BoNT injections for the neck muscles and\u002For oral pharmacological therapy.\n\nExclusion Criteria:\n\n* Participating in an alternate structured exercise program, receiving regular physical or occupational therapy\n* Have significant pain, spondylosis or active arthritis\n* Fail the Physical Activity Readiness Questionnaire\n* Have significant cognitive impairment\n* Have implanted electrical device (eg, cardiac pacemaker or a DBS or a neurostimulator or metallic clip in their body, as necessitated by the risks of MRI or TMS\n* Active seizure disorder; not be eligible for TMS and claustrophobic for MRI portion. As necessitated by the risks of MRI or TMS, patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain), active seizure disorder are not eligible for participation in the MRI or TMS portion of the study.\n* Pregnancy tests will be carried out for each female subject of child bearing potential prior to the participation in the study and prior to each follow up visit (as indicated).","30 Years",{"count":629,"type":19},56,[91],"The purpose of this research study is to investigate how the brain and motor behavior changes in individuals with dystonia in response to exercise training.",[25],"2025-07-23",{"date":635,"type":30},"2025-07-28",{"date":637,"type":30},"2022-10-13",{"date":639,"type":19},"2027-12-31",{"name":641,"class":77},"University of Florida"]